Clinical Trial

SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a prospective, randomized, two-cohort trial designed to evaluate the efficacy and safety of two regimens in the treatment of gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis: SHR-1701 combined with intravenous and intraperitoneal paclitaxel plus S-1, or SHR-1701 combined with CAPOX.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-24
Trial Details
NCT Number NCT07384234
Lead Sponsor Ruijin Hospital
Conditions Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Enrollment 60 participants
Start Date 2026-04-24
Primary Completion 2028-12-30 (estimated)
Study Completion 2030-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-23